Alle Storys
Folgen
Keine Story von Viroblock SA mehr verpassen.

Viroblock SA

Viroblock SA receives First Round of Equity Funding

Plan-les-Ouates (ots)

Viroblock SA, a start-up dedicated to
developing and commercializing a new generation of antiviral
products, today announced that it has completed its first round of
equity funding led by private investor Peter Pfister, Fongit Seed
Invest SA, and Initiative Capital Romandie SA.
Viroblock also announced that the newly appointed Board of
Directors will consist of Peter Pfister (Chairman), former CFO of
Adecco; Igor Fisch, CEO of Selexis SA; Daniel Fustier, former Global
Vice President of Covance and former head of Covance CLS SA in
Geneva; Donald Wallach, founder and former professor at Harvard
Medical School and Gian-Luigi Berini, an experienced hi-tech
entrepreneur and board member of Fongit Seed Invest. Georges Haas,
former Worldwide Head of Pharmaceutical Research and Preclinical
Development at Ciba-Geigy has joined the scientific advisory board.
"We are delighted to have both experienced business people and
accomplished scientists help us build the company. We are now excited
to start the validation of our outstanding in vitro results in
pre-clinical studies", said Thierry Pelet, CEO of Viroblock.
About Viroblock
Viroblock is dedicated to developing and commercializing a new
generation of antiviral products with a novel mechanism of action
against enveloped viruses. Enveloped viruses represent more than 60 %
of all existing viruses and include major human pathogens such as
human and avian influenzas, the hepatitis B and C viruses and the
AIDS virus.
Viroblock's unique proprietary products and technologies open very
promising opportunities in a number of prophylactic and therapeutic
applications.
Viroblock was founded in October 2005 by Donald Wallach, a
scientist and academic now residing in Geneva with past tenure at the
Harvard Medical School and Tufts University, and a pioneer in the
research of liposome systems. The W. A. de Vigier Foundation
nominated Viroblock as one of the 10 best technology projects of the
year 2006, and the Selection Committee of the Swiss Tech Tour 2007
rated Viroblock as one of the top technology companies in
Switzerland. Viroblock is based at the incubator FONGIT in
Plan-les-Ouates, Geneva.

Contact:

Thierry Pelet, CEO
Phone: +41/22/884'83'44
E-Mail: info@viroblock.com